Anika Therapeutics appoints Steven Chartier VP of regulatory and clinical affairs: 5 observations

Mackenzie Garrity -   Print  |

Anika Therapeutics, a global orthopedic medicines company, elected Steven Chartier to vice president of regulatory and clinical affairs.

Here are five observations:

 

1. Mr. Chartier brings more than 25 years of operational expertise leading global regulatory strategy and clinical development for emerging and established companies in medical technology and biotechnology industries.

 

2. In this role, Mr. Chartier is responsible for overseeing and directing the clinical development course for Anika Therapeutics' orthobiologics and regenerative medicine pipeline through U.S. and international channels.

 

3. Previously, Mr. Chartier served as vice president of regulatory affairs and quality assurance at Augmenix, a company focused on improving outcomes of radiotherapy through absorbable hydrogels.

 

4. Mr. Chartier has served as COO of Infraredx, a cardiovascular imaging company, where he developed broad operational prowess and led U.S. and global regulatory, quality and clinical development strategies.

 

5. Mr. Chartier received his regulatory affairs certification from the Regulatory Affairs Professional Society.

 

More articles on devices and implants:
Global powered surgical instruments market expected to exceed $2.6B by 2022: 3 takeaways
Spine implant segment leads global orthopedic devices market: 6 observations
4 trends in PEEK use for orthopedic, spine surgery

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers